New hope for myeloma patients: could a smart drug outperform standard therapy?
NCT ID NCT07285239
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial will compare two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or refuse a stem cell transplant. About 500 participants will receive either belantamab mafodotin or daratumumab, both combined with standard drugs (bortezomib, lenalidomide, and dexamethasone). The goal is to see if the belantamab combination leads to deeper cancer clearance (MRD negativity) and longer time without the disease progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted drug that delivers a toxin to cancer cells)
What this could lead to
If it works, this could offer a more effective first-line treatment option for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant.
What could go wrong
This is a large phase 3 trial, but it is not yet recruiting. The experimental drug may cause side effects like eye problems, and it is not known if it will be better than the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••